Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
In this article
Pharma thinks it’s found the next frontier in preventing heart attacks.
Novartis
, Amgen
and Eli Lilly
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer for treating high cholesterol.
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other…
The interim Phase I trial data was only from 35 people, but results look good so far.
‘Game-changer’ drugs that tackle a previously untreatable type of bad cholesterol could arrive by next year
As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the…
